Chronic lymphocytic leukaemia: from genetics to treatment

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

(2019) Anas Younes et al.   Lancet Haematology

Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia

(2019) Federico Gaiti et al.   NATURE

Biology and treatment of Richter syndrome

(2018) Davide Rossi et al.   BLOOD

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

(2018) Michael Hallek et al.   BLOOD

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

(2018) Susan O’Brien et al.   BLOOD

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

(2018) Jeffrey Jones et al.   BRITISH JOURNAL OF HAEMATOLOGY

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics

(2018) Gian Matteo Rigolin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations

(2018) Andreas Agathangelidis et al.   HAEMATOLOGICA

Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia

(2018) Idanna Innocenti et al.   HEMATOLOGICAL ONCOLOGY

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

(2018) Jeffrey A Jones et al.   LANCET ONCOLOGY

The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia

(2018) Renée Beekman et al.   NATURE MEDICINE

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

(2018) Jan A. Burger et al.   Nature Reviews Clinical Oncology

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

(2018) Carmen D. Herling et al.   Nature Communications

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations

(2018) Andreas Agathangelidis et al.   HAEMATOLOGICA

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

(2018) Paula Cramer et al.   LANCET ONCOLOGY

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

(2018) Ian W. Flinn et al.   BLOOD

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

(2018) Carol Moreno et al.   LANCET ONCOLOGY

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

(2018) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

(2017) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic landscape and deregulated pathways in B-cell lymphoid malignancies

(2017) R. Rosenquist et al.   JOURNAL OF INTERNAL MEDICINE

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity

(2017) S Marsilio et al.   LEUKEMIA

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

(2017) F Nadeu et al.   LEUKEMIA

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways

(2017) D Benedetti et al.   LEUKEMIA

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

(2017) J R Brown et al.   LEUKEMIA

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components

(2017) F Pozzo et al.   LEUKEMIA

Common nonmutationalNOTCH1activation in chronic lymphocytic leukemia

(2017) Giulia Fabbri et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia

(2017) Philip J. Law et al.   Nature Communications

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

(2017) Dan A. Landau et al.   Nature Communications

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

(2017) Jeffrey A Jones et al.   Lancet Haematology

Whole exome sequencing in families with CLL detects a variant in Integrin   2 associated with disease susceptibility

(2016) L. R. Goldin et al.   BLOOD

Clinical impact of MYD88 mutations in chronic lymphocytic leukemia

(2016) A. Martinez-Trillos et al.   BLOOD

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia

(2016) F. Nadeu et al.   BLOOD

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

(2016) C. D. Herling et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia

(2016) Lili Wang et al.   CANCER CELL

A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia

(2016) N. A. Amin et al.   CLINICAL CANCER RESEARCH

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation

(2016) Lijian Yu et al.   CLINICAL CANCER RESEARCH

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

(2016)   LANCET ONCOLOGY

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

(2016) Stephan Stilgenbauer et al.   LANCET ONCOLOGY

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

(2016) Susan O'Brien et al.   LANCET ONCOLOGY

Antigen receptor stereotypy in chronic lymphocytic leukemia

(2016) K Stamatopoulos et al.   LEUKEMIA

Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome

(2016) S Barrio et al.   LEUKEMIA

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Richter syndrome: pathogenesis and management

(2016) Davide Rossi et al.   SEMINARS IN ONCOLOGY

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

(2016) Jan A. Burger et al.   Nature Communications

A nationwide population-based cross-sectional comparison of hematological malignancies incidences between Taiwan and the United States of America

(2015) Shang-Ju Wu et al.   ANNALS OF HEMATOLOGY

Prognostic relevance of MYD88 mutations in CLL: the jury is still out

(2015) P. Baliakas et al.   BLOOD

A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia

(2015) S. M. O'Brien et al.   BLOOD

Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification

(2015) P. Strati et al.   BLOOD

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

(2015) P. A. Thompson et al.   BLOOD

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations

(2015) V. Ljungstrom et al.   BLOOD

Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia

(2015) Larry Mansouri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

(2015) Mohammed Z H Farooqui et al.   LANCET ONCOLOGY

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation

(2015) F Pozzo et al.   LEUKEMIA

Non-coding recurrent mutations in chronic lymphocytic leukaemia

(2015) Xose S. Puente et al.   NATURE

Mutations driving CLL and their evolution in progression and relapse

(2015) Dan A. Landau et al.   NATURE

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution

(2015) S. Kasar et al.   Nature Communications

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

(2015) Kami J. Maddocks et al.   JAMA Oncology

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

(2014) S. Stilgenbauer et al.   BLOOD

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

(2014) A. Martinez-Trillos et al.   BLOOD

Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness

(2014) M. Messina et al.   BLOOD

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia

(2014) D. Rossi et al.   BLOOD

Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia

(2014) Dan A. Landau et al.   CANCER CELL

Immunogenetic Studies of Chronic Lymphocytic Leukemia: Revelations and Speculations about Ontogeny and Clinical Evolution

(2014) A. Vardi et al.   CANCER RESEARCH

Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression

(2014) J Ojha et al.   LEUKEMIA

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

(2014) P Baliakas et al.   LEUKEMIA

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Resistance in Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients

(2014) F. Damm et al.   Cancer Discovery

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

(2013) E. Chigrinova et al.   BLOOD

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

(2013) P. Dreger et al.   BLOOD

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

(2013) P. Abrisqueta et al.   BLOOD

Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL

(2013) A. Vardi et al.   BLOOD

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

(2013) Dan A. Landau et al.   CELL

Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome

(2013) Giulia Fabbri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients

(2013) S Weissmann et al.   LEUKEMIA

Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia

(2013) F Arruga et al.   LEUKEMIA

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

(2013) S Jeromin et al.   LEUKEMIA

The role ofATMmutations and 11q deletions in disease progression in chronic lymphocytic leukemia

(2013) Tatjana Stankovic et al.   LEUKEMIA & LYMPHOMA

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia

(2013) Andrew J Ramsay et al.   NATURE GENETICS

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

(2012) A. Agathangelidis et al.   BLOOD

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

(2012) D. G. Oscier et al.   BLOOD

Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukemia

(2012) Fabio P. S. Santos et al.   CANCER JOURNAL

Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2012) Kate Cwynarski et al.   JOURNAL OF CLINICAL ONCOLOGY

Biallelic ATM Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial

(2012) Anna Skowronska et al.   JOURNAL OF CLINICAL ONCOLOGY

Cellular origin and pathophysiology of chronic lymphocytic leukemia

(2012) Marc Seifert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia

(2012) L Mansouri et al.   LEUKEMIA

NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

(2012) N Villamor et al.   LEUKEMIA

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

(2012) Marcus Dühren-von Minden et al.   NATURE

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia

(2012) Marta Kulis et al.   NATURE GENETICS

The Notch signalling system: recent insights into the complexity of a conserved pathway

(2012) K. G. Guruharsha et al.   NATURE REVIEWS GENETICS

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

(2011) X. C. Badoux et al.   BLOOD

NOTCH1 mutations in CLL associated with trisomy 12

(2011) V. Balatti et al.   BLOOD

Alteration of BIRC3 and multiple other NF- B pathway genes in splenic marginal zone lymphoma

(2011) D. Rossi et al.   BLOOD

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

(2011) D. Rossi et al.   BLOOD

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

(2011) D. Rossi et al.   BLOOD

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

(2011) D. Rossi et al.   BLOOD

Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia

(2011) Yoshikane Kikushige et al.   CANCER CELL

NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

(2011) I. Del Giudice et al.   HAEMATOLOGICA

Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia

(2011) Martin Trbusek et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

(2011) David Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia

(2011) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2011) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of the chronic lymphocytic leukemia coding genome: role ofNOTCH1mutational activation

(2011) Giulia Fabbri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults

(2011) J Almeida et al.   LEUKEMIA

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

(2011) Víctor Quesada et al.   NATURE GENETICS

SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

(2011) Lili Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

13q14 deletions in CLL involve cooperating tumor suppressors

(2010) A. Palamarchuk et al.   BLOOD

The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect

(2010) S.-J. Wu et al.   BLOOD

The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia

(2010) Ulf Klein et al.   CANCER CELL

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management

(2010) T D Shanafelt et al.   LEUKEMIA

Therapeutic antibody targeting of individual Notch receptors

(2010) Yan Wu et al.   NATURE

Prognostic factors in chronic lymphocytic leukemia—what do we need to know?

(2010) Paula Cramer et al.   Nature Reviews Clinical Oncology

Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience

(2009) P. Abrisqueta et al.   BLOOD

Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach

(2009) W. G. Nieto et al.   BLOOD

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

(2009) Francesc Bosch et al.   JOURNAL OF CLINICAL ONCOLOGY

B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia

(2009) Ola Landgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring

(2008) A. Dagklis et al.   BLOOD

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

(2008) T. Zenz et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression

(2008) Tait D. Shanafelt et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

(2008) Andy C. Rawstron et al.   NEW ENGLAND JOURNAL OF MEDICINE